<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516841</url>
  </required_header>
  <id_info>
    <org_study_id>206OC201</org_study_id>
    <nct_id>NCT00516841</nct_id>
  </id_info>
  <brief_title>A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Facet Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Facet Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with&#xD;
      platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision to terminate recruitment based on lack of efficacy&#xD;
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.</measure>
    <time_frame>Baseline, and every 8 weeks on study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>volociximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg volociximab once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volociximab</intervention_name>
    <description>15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops</description>
    <arm_group_label>volociximab</arm_group_label>
    <other_name>M200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must give written informed consent and any authorizations required by local law (e.g.,&#xD;
             Protected Health Information [PHI]).&#xD;
&#xD;
          -  Females aged ≥18 years old at the time of informed consent.&#xD;
&#xD;
          -  Advanced (Stage III or IV), histologically-documented epithelial ovarian cancer or&#xD;
             primary peritoneal cancer (excluding small, round-cell histologies).&#xD;
&#xD;
          -  Radiologically-documented evidence of progressive disease.&#xD;
&#xD;
          -  Platinum-resistant disease defined as having a best response of SD or disease&#xD;
             progression during or within 6 months of discontinuing a platinum-based chemotherapy&#xD;
             (carboplatinum, cisplatinum, or another organoplatinum compound).&#xD;
&#xD;
          -  Progression during or following treatment with topotecan or liposomal doxorubicin.&#xD;
&#xD;
          -  Three or fewer prior chemotherapy regimens (including a platinum-based therapy).&#xD;
&#xD;
          -  At least 1 measurable target lesion in accordance with RECIST criteria to assess&#xD;
             clinical response (tumors within a previously irradiated field are designated as&#xD;
             non-target).&#xD;
&#xD;
          -  ECOG Performance Status ≤1.&#xD;
&#xD;
          -  Life expectancy &gt;12 weeks.&#xD;
&#xD;
          -  Available paraffin block or unstained paraffin sections on glass slides containing&#xD;
             representative tumor tissue from the most recent tumor biopsy/resection.&#xD;
&#xD;
          -  Subjects of child-bearing potential must be willing to practice effective&#xD;
             contraception during the study and be willing and able to continue contraception for&#xD;
             at least 6 months after their last dose of study treatment (about 5 half lives).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Screening clinical laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1500/µL&#xD;
&#xD;
               -  Platelet count &lt;75,000/µL&#xD;
&#xD;
               -  Hemoglobin &lt;8.5 g/dL (hemoglobin may be supported by transfusion, erythropoietin,&#xD;
                  or other approved hematopoietic growth factors; darbopoeitin [Aranesp®] is&#xD;
                  permitted)&#xD;
&#xD;
               -  Serum bilirubin &gt;2.0 x upper limit of normal (ULN)&#xD;
&#xD;
               -  AST and ALT &gt;2.5 x ULN (AST and ALT &gt;5 × ULN for subjects with liver metastasis)&#xD;
&#xD;
               -  Serum creatinine &gt;2.0 mg/dL&#xD;
&#xD;
               -  International normalized ratio (INR) &gt;1.5&#xD;
&#xD;
               -  Activated partial thromboplastin time (aPTT) &gt;1.5 × ULN&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease.&#xD;
&#xD;
          -  Non-epithelial ovarian tumors.&#xD;
&#xD;
          -  Active infection requiring systemic antibiotics, antivirals, or antifungals including&#xD;
             HIV/AIDS, hepatitis B, or hepatitis C infection.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal&#xD;
             abscess within 6 months prior to Day 1.&#xD;
&#xD;
          -  Serious, non-healing wound, or bone fracture.&#xD;
&#xD;
          -  Known central nervous system or brain metastases.&#xD;
&#xD;
          -  History of uncontrolled psychiatric condition within 6 months prior to Day 1.&#xD;
&#xD;
          -  History of other malignancies within 3 years of Day 1, except for adequately treated&#xD;
             carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, or basal&#xD;
             or squamous cell skin cancer.&#xD;
&#xD;
          -  Evidence of autoimmune disease including, but not limited to, ulcerative colitis,&#xD;
             Crohn's disease, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)&#xD;
             sceloderma, or another diseases in which immune function or immune competence is known&#xD;
             to be impaired.&#xD;
&#xD;
          -  Any history of lymphoproliferative disorder.&#xD;
&#xD;
          -  Known human anti-murine antibody (HAMA) and/or human anti-chimeric antibody (HACA).&#xD;
&#xD;
          -  Any medical condition that may be exacerbated by bleeding, including a known bleeding&#xD;
             disorder such as a coagulation defect, thrombocytopenia, active gastric or duodenal&#xD;
             ulcer, or history of GI bleeding.&#xD;
&#xD;
          -  Significant hemoptysis within one year prior to Study Day 1.&#xD;
&#xD;
          -  Any investigational, anti-cancer therapy within 6 weeks prior to Day 1.&#xD;
&#xD;
          -  Any non-investigational, anti-cancer therapy within 4 weeks prior to Day 1.&#xD;
&#xD;
          -  Prior treatment with anti-angiogenic agents.&#xD;
&#xD;
          -  Subjects who require treatment with an anti-coagulant with the exception of low-dose&#xD;
             Aspirin® (≤81 mg/day), warfarin (≤1 mg/day), or heparin for IV catheter patency.&#xD;
&#xD;
          -  Subjects who are taking concomitant immunomodulatory agents including, but not limited&#xD;
             to, interferons, interleukins, systemic steroids, cyclosporine, tacrolimus,&#xD;
             calcineurin inhibitors, chronic low-dose methotrexate, or azathioprine. (The use of&#xD;
             inhaled or intranasal steroids or oral steroids at a dose of ≤10 mg/day prednisone or&#xD;
             its equivalent are permitted.)&#xD;
&#xD;
          -  Active, unstable severe cardiovascular disease, including poorly controlled angina,&#xD;
             congestive heart failure (CHF), arrhythmias, myocardial infarction (MI),&#xD;
             cardiomyopathy, atrioventricular (AV) block, electrocardiogram (ECG) evidence of acute&#xD;
             ischemia, or significant conduction abnormality.&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events, such as stroke, or transient&#xD;
             ischemic attack (TIA). (Note: Prior history of deep vein thrombosis will not exclude&#xD;
             subjects from participating in this study.)&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or lactating.&#xD;
&#xD;
          -  Inability to comply with study and follow-up procedures.&#xD;
&#xD;
          -  Any condition that, in the opinion of the Investigator, makes the subject unsuitable&#xD;
             for study participation.&#xD;
&#xD;
          -  Known hypersensitivity to murine or chimeric antibodies.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Matthews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Crowley Medical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minal Barve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Oncology PA, Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Burke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Billings Clinic (MCMRC network)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Glenn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Schilder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikki Spellman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma University Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Penson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Einstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Holloway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Armstrong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Kimmel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Snehel Bhoola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Health University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Winquist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernst Lengyel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Glaspy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA JCCC Clinical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krish Tewari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCI Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. William Helm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Glaspy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sawyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA JCCC Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic (MCMRC network)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA, Presbyterian</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>NGA4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>peritoneal cancer</keyword>
  <keyword>platinum-resistant ovarian cancer</keyword>
  <keyword>Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volociximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

